Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Sessionbenzinga_article·Jul 15 at 07:02 AMPOOL+0.24%ELV-0.43%
Fate Therapeutics wins FDA IND clearance for dual-target CAR-T candidate FT839PUBT·Jul 9 at 07:33 AMFATE-4.37%
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product CandidateUnusual Whales·Jul 9 at 07:31 AMFATE-4.37%
Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54Simplywall·Jul 6 at 11:06 AMFATE-4.37%
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual MeetingUnusual Whales·Jul 6 at 07:31 AMFATE-4.37%
Fate Therapeutics reports preliminary FT819 CAR-T data showing skin score improvement in systemic sclerosis patientsPUBT·Jul 6 at 07:31 AMFATE-4.37%
Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cashTradingView·Jun 4 at 03:43 PMFATE-4.37%
Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain DurabilityTip Ranks·Jun 4 at 01:25 PMFATE-4.37%
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune DiseasesUnusual Whales·May 21 at 07:33 AMFATE-4.37%FBT-0.57%
Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S ValuationSimplywall·May 14 at 09:14 PMFATE-4.37%SBIO-0.88%
Pre-market hot trades in US stocks: Fate Therap pre-market down 7.73%; MACOM Technology Solutions Holdings pre-market up 7.44%Price Alert·May 14 at 07:27 AMFATE-4.37%MTSI-5.60%
Gil Blum Maintains Hold Rating Amid Uncertainty on FT819 Durability and Rising Competition in Lupus Nephritis Cell TherapiesTip Ranks·May 13 at 01:45 PMFATE-4.37%SBIO-0.88%
Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution RisksTip Ranks·May 13 at 01:45 PMFATE-4.37%XBI-1.15%
